Hi, I am an happy lightbox
|
|
|
|
|
|
|
|
++ 32 (0)81 25 50 50
EN | NL | FR LOGIN   
PRODUCTS SECTORS SERVICES BRANDS
PRODUCTS
SECTORS
SERVICES
BRANDS
   
BECKMAN COULTER

Disease Management - Osteoporosis

What is Osteoporosis? Osteoporosis is a disease often with no detectable symptoms that affects millions of people in the world Often the first sign of Osteoporosis is a bone fracture in the hip or wrist
QUOTATION
INFORMATION
QUOTATION
INFORMATION
DESCRIPTION
DESCRIPTION
What is Osteoporosis?

Osteoporosis is a disease, often with no detectable symptoms, that affects millions of people in the world. Often the first sign of Osteoporosis is a bone fracture in the hip or wrist. Bone is always breaking down and rebuilding as part of the natural cycle, but when Osteoporosis strikes, this process is thrown out of balance. Bones can become brittle, many times resulting in debilitating fractures. This condition is especially common in postmenopausal women, and the lack of estrogen is believed to be the cause. Treatment often includes Hormone Replacement Therapy (HRT), bisphosphonate or calcitonin. Fortunately, postmenopausal osteoporosis in preventable.

What do I need to know?

There is new hope for managing Osteoporosis. A laboratory blood test, Ostase, can accurately measure how well bone is responding to hormone replacement therapy. The test measures the amount of a specific bone alkaline phosphotase (BAP) in the blood. This gives doctors a clear indication of whether the therapy is successful in reducing bone loss.

Why use Ostase?

Ostase, a biochemical marker of bone turnover, has been demonstrated effective in managing postmenopausal women on osteoporotic therapy. Ostase provides physicians and patients with a timely means of assessing therapy compliance and efficacy, whereas the traditional bone mineral density measurements require a minimum of one to two years to detect changes in bone. In addition, the blood-based Ostase test provides convenience and reliability, with a simple blood sample collection rather than a more variable urine test.

Currently, a bone mineral density test is required to diagnose Osteoporosis. If a diagnosis is confirmed, therapy begins. At this point, the physician and patient can choose how progress will be monitored. With Ostase as the follow-up test, the success of therapy can be documented after only six months. Bone mineral density tests, on the other hand, require a minimum of twelve to twenty-four months on therapy to detect changes in bone. With Ostase, you can see accurate, measurable results in less than half the time required of bone mineral density testing. Wouldn't you rather have the assurance of knowing, early on, that your therapy is working?


Features of the Beckman ACCESS OSTASE test
  • Quantitative measurement of bone-specific alkaline phosphatase (BAP), a biochemical marker of bone metabolism, in human serum and plasma
  • Time to first result: 30 minutes
  • Calibration stability: 28 days
  • Analytical senstivity: 0.1 µg/L
  • Broad dynamic range: 0.1 - 120 µg/L
  • Correlation with the Hybritech® Tandem® -R Ostase:

Access Ostase = 0.9985 x Tandem -R Ostase - 0.1135 (n=411; r = 0.9823)Characteristics

  • Sample Type/Size : Serum or plasma / 25 µL
  • Time to 1st Result : 30 minutes
  • Analytical Sensitivity : 0.1 µg/L
  • Calibrator Levels : 0, 7, 15, 30, 60 and 120 µg/L
  • Expected Range : See insert
  • Open Pack Stability : 28 days
  • Calibration Stability : 28 days
  • Protection : < 6.5 % CV
BECKMAN COULTER website
BECKMAN COULTER
Solutions and systems for clinical diagnostics (hematology, biochemistry, immunoassays, flow cytometry. Solutions for industry & research, for genetics, proteomics and cellular analysis. Lab automated workstation & liquid handling workstation.
This item belongs to the following categories (click to expand):
Prices are quoted in euro (taxes excluded) and apply in the Benelux (recycling fee included). They are subject to change without notice. We reserve the right to adjust pricing errors and to limit quantities.

FOLLOW US ON  FOLLOW US: